Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Clinical Trial to Evaluate the Efficacy and Safety of First Line Atezolizumab in Combination With Paclitaxel and Bevacizumab (Avastin®) in Patients With Advanced or Metastatic Triple-negative Breast Cancer

NCT04408118 is registered in ClinicalTrials.gov with MedSIR as lead sponsor.

NCT NCT04408118
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04408118 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Clinical Trial to Evaluate the Efficacy and Safety of First Line Atezolizumab in Combination With Paclitaxel and Bevacizumab (Avastin®) in Patients With Advanced or Metastatic Triple-negative Breast Cancer
Lead sponsor
MedSIR
Phase
Phase 2
Overall status
Completed
Start date
October 5, 2020
Completion date
December 7, 2023
Enrollment
100 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

advanced breast cancer, metastatic breast cancer, triple negative breast cancer